Patent Cooperation Treaty

ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Pharmaceutical, Alternative Medicine, Managed Care, Health, FDA, Clinical Trials, Other Health, Patent Cooperation Treaty, Pain, PAIN, Clinical trial, Safety, THC, Research, CBD, Patent, Pain management, Patient, Medicine, Cannabinoid, Cannabidiol, CBC, Chronic pain, Investigational New Drug, Pharmaceutical industry

ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announced today that the USPTO issued U.S. Patent No.

Key Points: 
  • ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announced today that the USPTO issued U.S. Patent No.
  • The patent, held by ZYUS’ wholly owned subsidiary, ZYUS Life Sciences Inc., is based on International Patent Application No.
  • This marks the seventh issuance of a patent in this patent family, joining other jurisdictions such as Canada, Australia, Israel, India, Korea and South Africa.
  • ZYUS’ intellectual property portfolio contains multiple patent families related to fixed-dose cannabinoid-based formulations for the treatment of pain and a variety of other clinically unmet needs.

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Retrieved on: 
Wednesday, March 27, 2024
Patent Cooperation Treaty, Depression, Selective serotonin reuptake inhibitor, Obesity, CWY, Patent, Central nervous system, SSRI, Patient, DSM-IV codes, Mental health, Anxiety, Therapy, USD, Pharmaceutical industry

Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression.
  • This application was previously filed as provisional patent application with the United States Patent and Trademark Office (“USPTO”).
  • Under our collaboration with SciSparc, we believe that our proprietary drugs can positively impact patients dealing with various forms of depression including treatment resistant depression," stated Dr. Adi Zuloff-Shani, CEO of Clearmind.
  • "We further believe that we have a tremendous opportunity to develop viable alternatives to the current SSRIs for individuals living with depression.

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Retrieved on: 
Wednesday, March 27, 2024
Patent Cooperation Treaty, Depression, Obesity, CWY, Central nervous system, DSM-IV codes, Anxiety, Patent, Therapy, Disorder, USD, TEL, Pharmaceutical industry

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.

Key Points: 
  • TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.
  • The patent application refers to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression.
  • According to the ResearchAndMarkets.com , the global depression and anxiety disorders treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Overall, as part of this collaboration, nine other patent applications have been filed by Clearmind with the USPTO for various compositions, including the composition of SciSparc’s CannAmide™with Clearmind’s MEAI compound for the treatment of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 12, 2024
The Orange Book, Patent Cooperation Treaty, Agitation, Administration, Conference call, Type, PCT, Conference, Database, Schizophrenia, Intelligence, Caregiver, Webcast, Patient, DSM-IV codes, Neuroscience, Fast Track, Food and Drug Administration, CMC, Wind, Orange Book, SCNC, Positive, Microsatellite instability, Dexmedetomidine, Clinical trial, Therapy, Safety, Patent, Research and development, Collection, FDA, Approved drug, Dementia, CAD, Food, Pharmaceutical industry

NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY clinical programs. In addition, the Company reported its financial results for the fourth quarter and full year 2023.

Key Points: 
  • In addition, the Company reported its financial results for the fourth quarter and full year 2023.
  • Net Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
  • Net Loss: BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
  • ET to provide an update on recent operational highlights and to discuss its fourth quarter and full year 2023 financial results.

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Central nervous system, Obesity, Patent, PCT, Patent Cooperation Treaty, MDMA, DSM-IV codes, Pharmaceutical industry

Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted three additional patent applications under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • In addition, seven patent applications were filed under the international PCT.
  • Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer, stated, “These latest patent applications are expected to significantly expand our IP protection, and further enhance our leadership in the psychedelic space.

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Central nervous system, TEL, Obesity, Ketamine, Patent, Ibogaine, PCT, Patent Cooperation Treaty, MDMA, PEA, CWY, Disorder, DSM-IV codes, Pharmaceutical industry

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
  • In addition, seven applications were filed under the PCT.

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Central nervous system, DMT, LSD, TEL, Patent, Patent Cooperation Treaty, Psilocybin, PEA, CWY, Disorder, Lysergic acid diethylamide

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
  • "We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc’s Chief Executive Officer, Oz Adler.
  • "We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutics advantages."

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Central nervous system, DMT, LSD, PCT, Patent Cooperation Treaty, Psilocybin, PEA, Patent, CWY, IP, Lysergic acid diethylamide, Research, Pharmaceutical industry

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.

Key Points: 
  • The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.
  • "Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry.
  • The PCT makes it possible for us to seek patent protection for our proprietary compounds in a large number of countries simultaneously which strengthens our IP portfolio.
  • The latest patent applications build upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.

Science and Technology Daily: A Closer Look at China's Innovation Efforts

Retrieved on: 
Wednesday, March 6, 2024
National Immigration Administration, Visa, Aircraft, United, Poverty, Multimedia, Research, Education, Aviation, Food, Tourism, Farmer, ID, Government, Patent Cooperation Treaty, Multilateralism, CPPCC, Behavior, C919, Two Sessions, Faculty, United Nations, STB, NPC, Policy, Singapore Airshow, Science, Agriculture, CAU, FAST, Environment, Student

Since enterprises are the main innovation makers, specific policies have been made to offer preferential taxation and financial support for high-tech enterprises to encourage innovation.

Key Points: 
  • Since enterprises are the main innovation makers, specific policies have been made to offer preferential taxation and financial support for high-tech enterprises to encourage innovation.
  • In its efforts to set ethical guardrails for developing science and technology, China introduced a range of trial measures for the ethical reviews of R&D activities.
  • Overall, these policies are designed to create a sound environment for sci-tech innovation and drive economic growth.
  • The domestically developed Fendouzhe has greatly improved the independent innovation level of China's deep-sea equipment technology.

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Retrieved on: 
Tuesday, March 5, 2024
RSV, Cancer, Messenger, Infection, FRA, Patent, APC, PCT, Patent Cooperation Treaty, HSV, Antibody, IMV, Peptide, Antigen, Protein, Intellectual property, Zika virus, Immune system, Vaccine

This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.

Key Points: 
  • This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.
  • This Patent has already been issued in the US, and is currently pending in the EU.
  • BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX™ compositions that comprise both a lipid-based adjuvant (i.e.
  • The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.